← Leaderboards
Sylvie E Blondelle
Torrey Pines Inst For Molecular Studies
$2,141,739
Attributed
$2,141,739
Total exposure
4
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $300K · FY2005–06$500K$375K$250K$125K$0
'05
'06
Funding mix
By agency
NIH$2,141,739 · 4
By mechanism
R21$1,080,000 · 2
R43$600,002 · 1
R01$461,737 · 1
Top collaborators
No co-investigators on record.
Most similar at Torrey Pines Inst For Molecular Studies
Same institution · by research overlap
- Darcy B Wilson$3,179,326
- Alan M Kleinfeld$7,429,134
- John M Ostresh$425,101
- Vipin Kumar$7,680,361
- Ronald T Ogata$2,780,402
Others in their field
Top investigators on “Human Tissue”
- David Heimbrook · Leidos Biomedical Research, Inc.$294,443,261
- Lawrence Corey · Fred Hutchinson Cancer Center$212,638,156
- Larry Arthur$131,303,476
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$114,079,276
- Peter Gordon Gillespie · Oregon Health And Science University$104,808,120
- Kevin Urdahl · Seattle Children'S Hospital$85,664,942
Research focus
Human TissueHuman Immunodeficiency Virus 1Peptide LibraryCytotoxic T LymphocytePeptidesMhc Class I AntigenCombinatorial ChemistryPeptide Chemical SynthesisTissue /Cell CultureVaccine DevelopmentLaboratory MouseEnzyme Linked Immunosorbent AssayDrug Design /Synthesis /ProductionCytotoxicityCell Mediated Lymphocytolysis TestCytokineConformationBiomimeticsAnalogHigh Performance Liquid ChromatographyHela CellsGlycoproteinsHuman Herpesvirus 8Genetic Library
Grant awards (8)
Immunogenic epitopes of rare HIV mutants as vaccines$300,001
R43 · FY2006 · DA · contact PI
Immunogenic epitopes of rare HIV mutants as vaccines$300,001
R43 · FY2005 · DA
Novel KSHV-specific CTL epitopes for development$270,000
R21 · FY2003 · DE
Novel KSHV-specific CTL epitopes for development$270,000
R21 · FY2002 · DE
OPTIMIZED HIV -SPECIFIC CTL ANTIGENS FOR VACCINE DESIGN$270,000
R21 · FY2002 · AI
OPTIMIZED HIV -SPECIFIC CTL ANTIGENS FOR VACCINE DESIGN$270,000
R21 · FY2001 · AI
HIGH AFFINITY AGONISTS OF HIV1 DEPENDENT FUSION$234,280
R01 · FY2001 · DE
HIGH AFFINITY AGONISTS OF HIV1 DEPENDENT FUSION$227,457
R01 · FY2000 · DE